White House

Just one cancer drug—ibrutinib—figures on the CMS list of 10 drugs subject to price negotiations under Medicare Part D
White House

Just one cancer drug—ibrutinib—figures on the CMS list of 10 drugs subject to price negotiations under Medicare Part D
PhRMA sues to block the program

The first 10 drugs selected for price negotiations under Medicare Part D program includes only one oncology drug: ibrutinib (Imbruvica), a tyrosine kinase inhibitor indicated for the treatment of blood cancers, including chronic lymphocytic leukemia and small lymphocytic lymphoma.